作者
Andrea Bezjak, Rebecca Paulus, Laurie E Gaspar, Robert D Timmerman, William L Straube, William F Ryan, Yolanda I Garces, Anthony T Pu, Anurag K Singh, Gregory M Videtic, Ronald C McGarry, Puneeth Iyengar, Jason R Pantarotto, James J Urbanic, Alexander Y Sun, Megan E Daly, Inga S Grills, Paul Sperduto, Daniel P Normolle, Jeffrey D Bradley, Hak Choy
发表日期
2019/5/20
期刊
Journal of Clinical Oncology
卷号
37
期号
15
页码范围
1316-1325
出版商
American Society of Clinical Oncology
简介
PURPOSE
Patients with centrally located early-stage non–small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic body radiotherapy (SBRT) for centrally located NSCLC.
MATERIALS AND METHODS
Medically inoperable patients with biopsy-proven, positron emission tomography–staged T1 to 2 (≤ 5 cm) N0M0 centrally located NSCLC were accrued into a dose-escalating, five-fraction SBRT schedule that ranged from 10 to 12 Gy/fraction (fx) delivered over 1.5 to 2 weeks. Dose-limiting toxicity (DLT) was defined as any treatment-related grade 3 or worse predefined toxicity that occurred within the first year. MTD was defined as the SBRT dose at which the probability of DLT was closest to 20% without exceeding it.
RESULTS
One …
学术搜索中的文章
A Bezjak, R Paulus, LE Gaspar, RD Timmerman… - Journal of Clinical Oncology, 2019